Safety and Efficacy of Xalkori ROS1


Last updated date
Study Location
Pfizer local country office
Tokyo, , , Japan


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Non-small Cell Lung Cancer
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients with past history of hypersensitivity to any of the ingredients of XALKORI


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Non-Small Cell Lung CancerStudy of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)
  1. Gainesville, Florida
18 Years+
Non-Small Cell Lung CancerEffect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy
  1. Gothenburg,
  2. Jönköping,
  3. Kalmar,
  4. Linköping,
  5. Lund,
  6. Malmö,
  7. Skövde,
  8. Trollhättan,
  9. Uddevalla,
  10. Umeå,
  11. Uppsala,
  12. Ystad,
  13. Örebro,
18 Years+
Non-Small Cell Lung CancerA Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)
  1. St. Louis, Missouri
18 Years+
Non-small Cell Lung CancerAn Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
  1. Boston, Massachusetts
  2. Middletown, New Jersey
  3. Pompton Plains, New Jersey
  4. Commack, New York
  5. Harrison, New York
  6. New York, New York
  7. New York, New York
  8. Uniondale, New York
  9. Houston, Texas
  10. Via Albertoni, Bologna
  11. Via Albertoni, Bologna
  12. Via Massarenti, Bologna
  13. Via Massarenti, Bologna
  14. Via Massarenti, Bologna
  15. Via Palagi, Bologna
  16. Milan, Lombardia
  17. Milan, Lombardia
  18. Milan, Lombardia
  19. Milan, Lombardia
  20. Milan, Lombardia
  21. Milan, Lombardia
  22. Milan, Lombardia
  23. Viale Pansini, Napli
  24. Amsterdam, Noord-holland
  25. Amsterdam,
  26. Groningen,
  27. Groningen,
  28. Cordoba,
  29. Los Angeles, California
  30. Santa Monica, California
  31. Norwich, Connecticut
  32. Norwich, Connecticut
  33. Altamonte Springs, Florida
  34. Bonita Springs, Florida
  35. Bradenton, Florida
  36. Brandon, Florida
  37. Cape Coral, Florida
  38. Clearwater, Florida
  39. Fleming Island, Florida
  40. Fort Myers, Florida
  41. Fort Myers, Florida
  42. Gainesville, Florida
  43. Largo, Florida
  44. Lecanto, Florida
  45. Naples, Florida
  46. New Port Richey, Florida
  47. Ocala, Florida
  48. Orange City, Florida
  49. Orlando, Florida
  50. Port Charlotte, Florida
  51. Saint Petersburg, Florida
  52. Saint Petersburg, Florida
  53. Sarasota, Florida
  54. Sarasota, Florida
  55. Spring Hill, Florida
  56. Tallahassee, Florida
  57. Tallahassee, Florida
  58. Tampa, Florida
  59. Tavares, Florida
  60. The Villages, Florida
  61. Venice, Florida
  62. Winter Park, Florida
  63. Atlanta, Georgia
  64. Atlanta, Georgia
  65. Atlanta, Georgia
  66. Atlanta, Georgia
  67. Johns Creek, Georgia
  68. Chicago, Illinois
  69. Overland Park, Kansas
  70. Baltimore, Maryland
  71. Baltimore, Maryland
  72. Baltimore, Maryland
  73. Baltimore, Maryland
  74. Boston, Massachusetts
  75. Boston, Massachusetts
  76. Boston, Massachusetts
  77. Boston, Massachusetts
  78. Boston, Massachusetts
  79. Boston, Massachusetts
  80. Chelsea, Massachusetts
  81. Stoneham, Massachusetts
  82. Stoneham, Massachusetts
  83. Creve Coeur, Missouri
  84. Independence, Missouri
  85. Kansas City, Missouri
  86. Saint Louis, Missouri
  87. Saint Louis, Missouri
  88. Saint Louis, Missouri
  89. Saint Louis, Missouri
  90. Basking Ridge, New Jersey
  91. Hackensack, New Jersey
  92. Montvale, New Jersey
  93. Bronx, New York
  94. Bronx, New York
  95. Bronx, New York
  96. New York, New York
  97. New York, New York
  98. New York, New York
  99. Durham, North Carolina
  100. Columbus, Ohio
  101. Columbus, Ohio
  102. Columbus, Ohio
  103. Columbus, Ohio
  104. Columbus, Ohio
  105. Columbus, Ohio
  106. Columbus, Ohio
  107. Gahanna, Ohio
  108. Lewis Center, Ohio
  109. Clackamas, Oregon
  110. Newberg, Oregon
  111. Portland, Oregon
  112. Portland, Oregon
  113. Pittsburgh, Pennsylvania
  114. Pittsburgh, Pennsylvania
  115. Pittsburgh, Pennsylvania
  116. Pittsburgh, Pennsylvania
  117. York, Pennsylvania
  118. Chattanooga, Tennessee
  119. Chattanooga, Tennessee
  120. Chattanooga, Tennessee
  121. Cleveland, Tennessee
  122. Dickson, Tennessee
  123. Franklin, Tennessee
  124. Gallatin, Tennessee
  125. Hendersonville, Tennessee
  126. Hermitage, Tennessee
  127. Lebanon, Tennessee
  128. Murfreesboro, Tennessee
  129. Nashville, Tennessee
  130. Nashville, Tennessee
  131. Nashville, Tennessee
  132. Nashville, Tennessee
  133. Shelbyville, Tennessee
  134. Smyrna, Tennessee
  135. Houston, Texas
  136. Houston, Texas
  137. Kingwood, Texas
  138. Shenandoah, Texas
  139. The Woodlands, Texas
  140. Seattle, Washington
  141. Faenza, Emilia-romagna
  142. Lugo, Emilia-romagna
  143. Ravenna, Emilia-romagna
  144. Ravenna, Emilia-romagna
  145. Rimini, Emilia-romagna
  146. Roma, Lazio
  147. Milano, Lombardia
  148. Napoli, Naples
  149. Cattolica, Rimini
  150. Orbassano, Torino
  151. Orbassano, Torino
  152. Orbassano, Torino
  153. Orbassano, Torino
  154. Orbassano, Torino
  155. Orbassano, Torino
  156. Orbassano, Torino
  157. Milano,
  158. Napoli,
  159. Torino,
  160. Goyang-si, Gyeonggido
  161. Jeonnam,
  162. Seoul,
  163. Seoul,
  164. Seoul,
  165. Amsterdam, Noord-holland
  166. Majadahonda, Madrid
  167. Malaga, Málaga
  168. Barcelona,
  169. Barcelona,
  170. Barcelona,
  171. Barcelona,
  172. Barcelona,
  173. Cordoba,
  174. Cordoba,
  175. Esplugues de Llobregat,
  176. Hospitalet de Llobregat,
  177. L'Hospitalet,
  178. Madrid,
  179. Madrid,
  180. Malaga,
  181. Sevilla,
  182. Sevilla,
  183. Sevilla,
18 Years+
Advanced Information
Descriptive Information
Brief Title Safety and Efficacy of Xalkori ROS1
Brief Summary The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population 100 patients
Condition Non-small Cell Lung Cancer
Intervention Drug: crizotinib
XALKORI® Capsule 200 mg?XALKORI® Capsule 250 mg Frequency and duration are according to Package Insert as follows. " The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
Other Name: XALKORI® Capsule 200 mg?XALKORI® Capsule 250 mg
Study Groups/Cohorts crizotinib
Intervention: Drug: crizotinib
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: December 12, 2017)
Original Estimated Enrollment Same as current
Estimated Study Completion Date March 14, 2022
Estimated Primary Completion Date March 14, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • patients with unresectable progressive/recurrent NSCLC who are naive to XALKORI and whose tumor is ROS1 gene positive

Exclusion Criteria:

  • Patients with past history of hypersensitivity to any of the ingredients of XALKORI
Sexes Eligible for Study:All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contact: Pfizer Call Center1-800-718-1021[email protected]
Listed Location Countries Japan
Removed Location Countries  
Administrative Information
NCT Number NCT03375242
Other Study ID Numbers A8081051
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at:….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Study Director:Pfizer Call CenterPfizer
PRS Account Pfizer
Verification Date March 2020